Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study

Journal of the National Cancer Institute

Volumn 90, Issue 4, 1998, Pages 300-306

  Szebeni, Janos ^a   Muggia, Franco M ^b,c   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; CYCLOSPORIN A; DOCETAXEL; PACLITAXEL;

ANAPHYLAXIS; ARTICLE; COMPLEMENT ACTIVATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUSHING; HUMAN; HUMAN CELL; IN VITRO STUDY; POLYMERIZATION; RASH;

EID: 0032542499     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.4.300     Document Type: Article

References (43)

1. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987;5:1232-9.
2. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase 1 clinical and pharmacokinetic study of taxol. Cancer Res 1987;47: 2486-93.
3. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19:646-62.
4. Bristol-Myers Squibb Oncology Products Division, Princeton (NJ). Paxitaxel (Taxol) package insert. 1993.
5. Rowinsky EK. Clinical pharmacology of Taxol. Monogr Natl Cancer Inst 1993;15:25-37.
6. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20(4 Suppl 3):1-15.
7. Rowinsky EK, Donehower RC. The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 1993;20(4 Suppl 3):16-25.
8. Sharma A, Mayhew E, Straubinger RM. Antitumor effects of Taxolcontaining liposomes in a taxol-resistant murine tumor model. Cancer Res 1993;53:5877-81.
9. Rowinsky EK, Wright M, Monsarrat B, Donehower RC. Clinical pharmacology and metabolism of taxol (paclitaxel): update 1993. Ann Oncol 1994;5 Suppl 6:S7-16.
10. Guchelaar HJ, ten Napel CH, de Vries EG, Mulder NH. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol 1994;6:40-8.
11. Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996;97(1 Pt 1):42-6.
12. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
13. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
14. Muller K. Untersuchungen uber Cremophor EL. Tenside 1966;3:37-45.
15. Garcia AA, Parimoo D, Dimery I, Rogers M, Jeffers S, Muggia FM. Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule. Semin Oncol 1997;24(Suppl 19):S19-62-S19-66.
16. O'Brien ME, Souberbielle BE. Allergic reactions to cytotoxic drugs - an update. Ann Oncol 1992;3:605-10.
17. Decorti G, Bartoli Klugmann F, Candussio L, Baldini L. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Anticancer Res 1996;16:317-20.
18. Lorenz W, Riemann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, et al. Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent. Agents Actions 1977;7:63-7.
19. Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br Med J 1980;280:1353.
20. Howrie DL, Ptachcinski RJ, Griffith BP, Hardesty RJ, Rosenthal JT, Burckart GJ, et al. Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell Clin Pharm 1985;19:425-7.
21. Lassus M, Scott D, Leyland-Jones B. Allergic reactions associated with cremophor-containing antineoplastics (abstract). Proc ASCO 1985;4: 268.
22. Nolte H, Carstensen H, Hertz H. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatr Hematol Oncol 1988;10:308-12.
23. Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JH, et al. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993;11:885-90.
24. Theis JG, Liau-Chu M, Chan HS, Doyle J, Greenberg ML, Koren G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol 1995;13:2508-16.
25. Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first-and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995;22(2 Suppl 4):22-9.
26. Mounier P, Laroche D, Divanon F, Mosquet B, Vergnaud MC, EsseComlan A, et al. Anaphylactoid reactions to an injectable solution of a cremophor-containing solution of multivitamins. Therapie 1995;50:571-3.
27. Huttel MS, Schou Olesen A, Stoffersen E. Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR). Br J Anaesth 1980; 52:77-9.
28. Cheung AK. The complement system in extracorporeal circulation. Plasma Ther Transfus Technol 1984;5:505-16.
29. Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM. Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis. Artif Organs 1994;18:880-887.
30. Marceau F, Lundberg C, Hugh TE. Effects of anaphylatoxins on circulation. Immunopharmacology 1987;14:67-84.
31. Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollen AM, et al. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 1996;88:1297-301.
32. Blum RH, Garnick MB, Israel M, Canellos GP, Henderson IC, Frei E 3d. Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep 1979;63:919-23.
33. O'Dwyer PJ, Weiss RB. Hypersensitivity reactions induced by etoposide. Cancer Treat Rep 1984;68:959-61.
34. Athanassiou AE, Bafaloukos D, Pectasidis D, Dimitriadis M. Acute vasomotor response - a reaction to etoposide [letter]. J Clin Oncol 1988;6: 1204-5.
35. Laver AJ, Hibbs M, Smith RA. Activation of complement by DMSO and ethanol and its inhibition by soluble complement receptor type 1. Biochem Soc Trans 1995;23:167S.
36. Hunter RL, Bennett B. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J Immunol 1984;133:3167-75.
37. Hunter RL, Bennett B. Modulation of antigen presentation and host mediators by block copolymer adjuvants. Prog Leuk Biol 1987;6:181-90.
38. Hunter RL. Nonionic block polymers: new preparations and review of the mechanism of action. In: Levine MM, editor. New Generation Vaccines. New York: Marcel Dekker, 1990.
39. Alving CR, Swartz GM Jr. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit Rev Immunol 1991;10:441-53.
40. Wassef NM, Johnson SH, Graeber GM, Swartz GM Jr, Schultz CL, Hailey JR, et al. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J Immunol 1989;143:2990-5.
41. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, et al. Soluble complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-51.
42. Cheung AK, Parker CJ, Hohnholt M. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 1994;46:1680-7.
43. Gibb AL, Freeman AM, Smith RA, Edmonds S, Sim E. The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4. Biochim Biophys Acta 1993;1180:313-20.